BCL2 mutations in diffuse large B-cell lymphoma

Leukemia

Volumn 26, Issue 6, 2012, Pages 1383-1390

  Schuetz, J M ^a   Johnson, N A ^b   Morin, R D ^a   Scott, D W ^c   Tan, K ^c   Ben Nierah, S ^c   Boyle, M ^c   Slack, G W ^c   Marra, M A ^a   Connors, J M ^d   Brooks Wilson, A R ^a,e   Gascoyne, R D ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e SIMON FRASER UNIVERSITY   (Canada)

Author keywords

BCL2; DLBCL; lymphoma; RNA seq; somatic hypermutation; t(14; 18)

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ARTICLE; BCL2 GENE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LYMPHATIC LEUKEMIA; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; SMALL LYMPHOCYTIC LEUKEMIA;

EID: 84862016740     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.378     Document Type: Article

References (54)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. IARC: Lyon, France, 2008.
2. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511. (Pubitemid 30082188)
3. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 1984; 226: 1097-1099. (Pubitemid 15217831)
4. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440-442.
5. Willis TG, Dyer MJ. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood 2000; 96: 808-822. (Pubitemid 30618048)
6. Iqbal J, Sanger WG, Horsman DE, Rosenwald A, Pickering DL, Dave B et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol 2004; 165: 159-166. (Pubitemid 38821823)
7. Iqbal J, Neppalli VT, Wright G, Dave BJ, Horsman DE, Rosenwald A et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 961-968. (Pubitemid 46638851)
8. Saito M, Novak U, Piovan E, Basso K, Sumazin P, Schneider C et al. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2009; 106: 11294-11299.
9. Masir N, Campbell LJ, Jones M, Mason DY. Pseudonegative BCL2 protein expression in a t(14;18) translocation positive lymphoma cell line: a need for an alternative BCL2 antibody. Pathology 2010; 42: 212-216.
10. Schraders M, de Jong D, Kluin P, Groenen P, van Krieken H. Lack of Bcl-2 expression in follicular lymphoma may be caused by mutations in the BCL2 gene or by absence of the t(14;18) translocation. J Pathol 2005; 205: 329-335. (Pubitemid 40253923)
11. Hermine O, Haioun C, Lepage E, d'Agay MF, Briere J, Lavignac C et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996; 87: 265-272.
12. Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101: 4279-4284. (Pubitemid 36857789)
13. Jovanovic MP, Jakovic L, Bogdanovic A, Markovic O, Martinovic VC, Mihaljevic B. Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells. Vojnosanit Pregl 2009; 66: 738-743.
14. Iqbal J, Meyer PN, Smith L, Johnson NA, Vose JM, Greiner TC et al. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and Rituximab. Clin Cancer Res 2011; 17: 7785-7795.
15. Gurudutta GU, Verma YK, Singh VK, Gupta P, Raj HG, Sharma RK et al. Structural conservation of residues in BH1 and BH2 domains of Bcl-2 family proteins. FEBS Lett 2005; 579: 3503-3507. (Pubitemid 40897684)
16. Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997; 275: 983-986. (Pubitemid 27087715)
17. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 2008; 5: 621-628. (Pubitemid 351911867)
18. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42: 181-185.
19. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476: 298-303.
20. Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009; 114: 3533-3537.
21. Shustik J, Han G, Farinha P, Johnson NA, Ben Neriah S, Connors JM et al. Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. Haematologica 2010; 95: 96-101.
22. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282. (Pubitemid 38029949)
23. Horsman DE, Connors JM, Pantzar T, Gascoyne RD. Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). Genes Chromosomes Cancer 2001; 30: 375-382. (Pubitemid 32216328)
24. Bentley G, Palutke M, Mohamed AN. Variant t(14;18) in malignant lymphoma: a report of seven cases. Cancer Genet Cytogenet 2005; 157: 12-17. (Pubitemid 40164852)
25. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-1760.
26. Goya R, Sun MG, Morin RD, Leung G, Ha G, Wiegand KC et al. SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors. Bioinformatics 2010; 26: 730-736.
27. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000; 132: 365-386.
28. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res 2002; 30: 3894-3900. (Pubitemid 35012462)
29. Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RS, Kuppers R et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001; 412: 341-346. (Pubitemid 32691848)
30. Weber JS, Berry J, Litwin S, Claflin JL. Somatic hypermutation of the JC intron is markedly reduced in unrearranged kappa and H alleles and is unevenly distributed in rearranged alleles. J Immunol 1991; 146: 3218-3226.
31. Peled JU, Kuang FL, Iglesias-Ussel MD, Roa S, Kalis SL, Goodman MF et al. The biochemistry of somatic hypermutation. Annu Rev Immunol 2008; 26: 481-511. (Pubitemid 351600383)
32. Tanaka S, Louie DC, Kant JA, Reed JC. Frequent incidence of somatic mutations in translocated BCL2 oncogenes of non-Hodgkin's lymphomas. Blood 1992; 79: 229-237.
33. Liu M, Duke JL, Richter DJ, Vinuesa CG, Goodnow CC, Kleinstein SH et al. Two levels of protection for the B cell genome during somatic hypermutation. Nature 2008; 451: 841-845. (Pubitemid 351253166)
34. Deng X, Gao F, Flagg T, Anderson J, May WS. Bcl2's flexible loop domain regulates p53 binding and survival. Mol Cell Biol 2006; 26: 4421-4434. (Pubitemid 43877564)
35. Cheng EH, Kirsch DG, Clem RJ, Ravi R, Kastan MB, Bedi A et al. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 1997; 278: 1966-1968. (Pubitemid 28013242)
36. Grandgirard D, Studer E, Monney L, Belser T, Fellay I, Borner C et al. Alphaviruses induce apoptosis in Bcl-2-overexpressing cells: evidence for a caspase-mediated, proteolytic inactivation of Bcl-2. EMBO J 1998; 17: 1268-1278. (Pubitemid 28105506)
37. Lin B, Kolluri SK, Lin F, Liu W, Han YH, Cao X et al. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 2004; 116: 527-540. (Pubitemid 38264430)
38. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007; 12: 171-185. (Pubitemid 47199122)
39. Seto M, Jaeger U, Hockett RD, Graninger W, Bennett S, Goldman P et al. Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J 1988; 7: 123-131.
40. Tanaka S, Louie D, Kant J, Reed JC. Application of a PCR-mismatch technique to the BCL-2 gene: detection of point mutations in BCL-2 genes of malignancies with A t(14,18). Leukemia 1992; 6 (Suppl 3): 15S-19S.
41. Pappa VI, Wilkes S, Norton A, Phillips S, Rohatiner AZS, Lister TA et al. Detection of somatic mutations of the bcl-2 oncogene in B cell lymphomas with the t(14;18). Int J Oncol 1997; 11: 481-488. (Pubitemid 27364279)
42. Chang BS, Minn AJ, Muchmore SW, Fesik SW, Thompson CB. Identification of a novel regulatory domain in Bcl-X(L) and Bcl-2. EMBO J 1997; 16: 968-977. (Pubitemid 27113176)
43. Srivastava RK, Mi QS, Hardwick JM, Longo DL. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci USA 1999; 96: 3775-3780. (Pubitemid 29168986)
44. Uhlmann EJ, D'Sa-Eipper C, Subramanian T, Wagner AJ, Hay N, Chinnadurai G. Deletion of a nonconserved region of Bcl-2 confers a novel gain of function: suppression of apoptosis with concomitant cell proliferation. Cancer Res 1996; 56: 2506-2509. (Pubitemid 26170683)
45. Mazel S, Burtrum D, Petrie HT. Regulation of cell division cycle progression by bcl-2 expression: a potential mechanism for inhibition of programmed cell death. J Exp Med 1996; 183: 2219-2226. (Pubitemid 26158913)
46. O'Reilly LA, Huang DC, Strasser A. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J 1996; 15: 6979-6990. (Pubitemid 27023269)
47. Komaki S, Kohno M, Matsuura N, Shimadzu M, Adachi N, Hoshide R et al. The polymorphic 43Thr bcl-2 protein confers relative resistance to autoimmunity: an analytical evaluation. Hum Genet 1998; 103: 435-440. (Pubitemid 28542954)
48. Petros AM, Gunasekera A, Xu N, Olejniczak ET, Fesik SW. Defining the p53 DNA-binding domain/Bcl-x(L)-binding interface using NMR. FEBS Lett 2004; 559: 171-174. (Pubitemid 38186723)
49. Deng X, Gao F, Flagg T, May Jr WS. Mono-and multisite phosphorylation enhances Bcl2's antiapoptotic function and inhibition of cell cycle entry functions. Proc Natl Acad Sci USA 2004; 101: 153-158. (Pubitemid 38084219)
50. Wei Y, Pattingre S, Sinha S, Bassik M, Levine B. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol Cell 2008; 30: 678-688. (Pubitemid 351818252)
51. Deng X, Gao F, May Jr WS. Bcl2 retards G1/S cell cycle transition by regulating intracellular ROS. Blood 2003; 102: 3179-3185. (Pubitemid 37314754)
52. Vogler M, Dinsdale D, Sun XM, Young KW, Butterworth M, Nicotera P et al. A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells. Cell Death Differ 2008; 15: 820-830. (Pubitemid 351524424)
53. Pinton P, Rizzuto R. Bcl-2 and Ca2+ homeostasis in the endoplasmic reticulum. Cell Death Differ 2006; 13: 1409-1418. (Pubitemid 44057477)
54. Tomita Y, Marchenko N, Erster S, Nemajerova A, Dehner A, Klein C et al. WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem 2006; 281: 8600-8606. (Pubitemid 43847963)